Form 4: Denali Therapeutics Director Nancy Thornberry Receives Significant Equity Grant

Denali Therapeutics Inc. Director Nancy Thornberry was granted 6,037 Restricted Stock Units and 18,111 stock options on June 3, 2025, as part of her compensation.

Summary

• Nancy Thornberry, a Director at Denali Therapeutics Inc. (DNLI), reported changes in her beneficial ownership of company securities.
• On June 3, 2025, she acquired 6,037 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.
• She also acquired 18,111 stock options to purchase Common Stock, with an exercise price of $13.93 per share.
• Both the RSUs and stock options are subject to vesting, which occurs upon the earlier of the one-year anniversary of the grant date or the day preceding the Issuer's next annual meeting of stockholders after the grant date.
• Following these transactions, Nancy Thornberry beneficially owns 24,717 shares of Common Stock, which includes the 6,037 unvested RSUs.

Sentiment

Score: 7

Explanation: The document reports an equity grant to a director, which is generally a positive sign of alignment and retention. It does not contain negative financial news or operational setbacks. The score is not higher because it's a routine compensation event rather than a significant positive operational or financial announcement.

Positives

• The grant of Restricted Stock Units (RSUs) and stock options aligns the director's interests with long-term shareholder value.
• The acquisition of equity compensation indicates continued commitment of a key director to the company.

Risks

• Potential dilution risk for existing shareholders due to the future issuance of new shares upon vesting of RSUs and exercise of options.
• Future stock price volatility could impact the actual value realized from the granted equity.

Future Outlook

The vesting schedules for the granted RSUs and stock options indicate that the director's equity will become fully vested upon the earlier of the one-year anniversary of the grant date or the day preceding the company's next annual meeting of stockholders occurring after the grant date, aligning future incentives.

Industry Context

This Form 4 filing reflects a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, where stock options and restricted stock units are common tools to attract, retain, and incentivize key personnel by aligning their interests with long-term company performance and shareholder value. Such grants are standard practice across many publicly traded companies, particularly in high-growth sectors like biotech.

Comparison to Industry Standards

• Equity grants to directors, including RSUs and stock options, are a standard component of compensation packages across publicly traded companies, particularly in the biotech sector.
• The specific number of units and options granted to Nancy Thornberry would typically be benchmarked against compensation practices at peer companies of similar size and stage (e.g., Biogen, Amgen, Gilead Sciences, Vertex Pharmaceuticals) to ensure competitive and appropriate remuneration for board service.
• The vesting schedule (one-year anniversary or next annual meeting) is also a common structure designed to encourage continued service and long-term commitment.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting/exercise, but also increased alignment of director's interests with shareholder value.

Next Steps

• The RSUs and stock options will vest according to the specified schedule (earlier of one-year anniversary of grant date or day preceding next annual meeting).
• The director may exercise the stock options at the specified exercise price before the expiration date of June 3, 2035.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership